POGZ Inhibitors
Chemical inhibitors of POGZ can modulate its function by targeting the cell cycle mechanisms in which it is involved. Alsterpaullone, Roscovitine, Olomoucine, Purvalanol A, Flavopiridol, Dinaciclib, and SNS-032 are known to inhibit cyclin-dependent kinases (CDKs), which are crucial in the regulation of the cell cycle. Alsterpaullone achieves this by acting as a potent antagonist to CDKs, thereby directly affecting the function of POGZ associated with cell cycle progression. Roscovitine, with its selective inhibition of CDKs, can interfere with the progression of the cell cycle, leading to a functional inhibition of POGZ. Similarly, Olomoucine's action on CDKs can suppress POGZ's activity by disrupting the cell cycle phases it regulates. Purvalanol A's targeting of CDKs disrupts the precise control of the cell cycle that POGZ might influence, while Flavopiridol, with its broader range of CDK inhibition, can affect multiple points of the cell cycle where POGZ is active.
Continuing with this theme, Dinaciclib's potent inhibition of CDKs can halt the cell cycle events regulated by POGZ, impacting its functional role. SNS-032 goes a step further by not only affecting cell cycle progression but also transcription regulation, which are processes where POGZ plays a regulatory role. Milciclib, although primarily a CDK inhibitor, also targets other kinases involved in cell cycle control, which can disrupt the kinase-dependent regulatory pathways of POGZ. PD0332991 (Palbociclib), Ribociclib, and Abemaciclib specifically inhibit CDK4/6, which leads to an arrest in the G1 phase of the cell cycle. This action can functionally inhibit POGZ by preventing the cell cycle from progressing past a phase where POGZ is functionally significant. LEE011, another name for Ribociclib, reinforces this inhibition of CDK4/6, further solidifying the functional impediment of POGZ at the G1 phase checkpoint. Through these mechanisms, the selected chemicals can modulate the activity of POGZ by directly disrupting the cellular processes it regulates.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a known inhibitor of cyclin-dependent kinases (CDKs). POGZ has been associated with cell cycle regulation. By inhibiting CDKs, Alsterpaullone can interfere with the cell cycle progression, thereby inhibiting the functional involvement of POGZ in cell cycle-related processes. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine selectively inhibits CDKs, which are essential for cell cycle progression. Since POGZ is implicated in the regulation of the cell cycle, inhibition of CDKs by Roscovitine can lead to a functional inhibition of POGZ by preventing the cell cycle events that POGZ would normally regulate. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is another CDK inhibitor that can halt cell cycle progression. Inhibition of CDKs can suppress the functional activity of POGZ by disrupting the cell cycle phases that POGZ is known to influence, hence functionally inhibiting POGZ. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A is an inhibitor of CDKs, and by inhibiting these kinases, it can disrupt the cell cycle control in which POGZ is involved, leading to a functional inhibition of POGZ's role in cell cycle regulation. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits multiple CDKs and can thereby disrupt the cell cycle. As POGZ plays a role in cell cycle regulation, the inhibition of CDKs by Flavopiridol can functionally inhibit POGZ by impeding the cell cycle-related functions POGZ is known to influence. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is a potent CDK inhibitor affecting cell cycle progression. By inhibiting CDKs, Dinaciclib can functionally inhibit POGZ by preventing the cell cycle-related activities that POGZ regulates, thus halting its functional contribution to cell cycle control. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
PD0332991, also known as Palbociclib, is a selective inhibitor of CDK4/6, which are important for cell cycle G1 phase progression. POGZ has been implicated in cell cycle regulation, and therefore Palbociclib can functionally inhibit POGZ by arresting the cell cycle at the G1 phase where POGZ may exert its regulatory functions. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib selectively inhibits CDK4/6, leading to G1 phase arrest in the cell cycle. Since POGZ is involved in the regulation of the cell cycle, Ribociclib can functionally inhibit POGZ by disrupting the G1 phase events that POGZ is known to influence. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib is an inhibitor of CDK4/6, preventing progression from the G1 to S phase of the cell cycle. POGZ is implicated in cell cycle regulation, and by inhibiting CDK4/6, Abemaciclib can functionally inhibit POGZ by halting the cell cycle at a point where POGZ may be functionally active. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a CDK inhibitor that affects cell cycle progression and transcription regulation. The inhibition of CDKs can lead to a functional inhibition of POGZ by impeding the cell cycle and transcriptional events that POGZ is implicated in regulating. | ||||||